Drug intelligence / Profile preview

Ab1 (Biocytogen)

Development stage
Preclinical
Lead developer
Biocytogen
Modality
Antibody-Based Therapeutics
01

Overview

Ab1 (Biocytogen): sourced facts only. name: "Biocytogen developed a BsAb Ab1 that targets human CD3 and human HER2, and evaluated its efficacy and mechanism of action in preclinical studies." [DOI:10.1158/1538-7445.am2025-1279]; target: "Biocytogen developed a BsAb Ab1 that targets human CD3 and human HER2, and evaluated its efficacy and mechanism of action in preclinical studies." [DOI:10.1158/1538-7445.am2025-1279]; developer: "Biocytogen developed a BsAb Ab1 that targets human CD3 and human HER2, and evaluated its efficacy and mechanism of action in preclinical studies." [DOI:10.1158/1538-7445.am2025-1279]; modality: "Biocytogen developed a BsAb Ab1 that targets human CD3 and human HER2, and evaluated its efficacy and mechanism of action in preclinical studies." [DOI:10.1158/1538-7445.am2025-1279]; stage: "In a syngeneic transplantation model using B-hCD3E/hHER2 mice inoculated with the B-hHER2 MC38 plus cell line, BsAb Ab1 effectively inhibited tumor growth." [DOI:10.1158/1538-7445.am2025-1279]

02

Targets

ERBB2 (Erb-b2 receptor tyrosine kinase 2)

Beyond the preview

Go deeper on Ab1 (Biocytogen).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Ab1 (Biocytogen).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call